Table 2. Clinical characteristics of patients by use of HT (2010–2015).
| Characteristics | HT (n=1,140) | Control (n=7,606) | p-value | |
|---|---|---|---|---|
| Age (yr) | <0.001 | |||
| <30 | 18 (2) | 44 (1) | ||
| 31–40 | 134 (12) | 421 (6) | ||
| 41–50 | 389 (34) | 1,448 (19) | ||
| 51–60 | 477 (42) | 3,224 (42) | ||
| 61–70 | 90 (8) | 1,735 (23) | ||
| >70 | 32 (3) | 734 (10) | ||
| Lymphadenectomy | 0.051 | |||
| No | 274 (24) | 1,633 (21) | ||
| Yes | 866 (76) | 5,973 (79) | ||
| Adjuvant therapy | <0.001 | |||
| No | 874 (77) | 5,219 (69) | ||
| Brachytherapy | 27 (2) | 378 (5) | ||
| Radiotherapy | 58 (5) | 497 (7) | ||
| Chemotherapy | 181 (16) | 1,512 (20) | ||
| Type of HT | - | |||
| Estrogen only | 253 (22) | - | ||
| Estrogen plus progesterone | 178 (16) | - | ||
| Tibolone | 363 (32) | - | ||
| Progesterone only | 346 (30) | - | ||
Values are presented as number of patients (%).
HT, hormone therapy.